 Aldeyra Therapeutics Incs NASDAQ: ALDX reproxalap achieved the primary endpoint of ocular redness in the Phase 2 trial in patients with dry eye disease. But the ocular redness scores in the reproxalap group were statistically lower than those of vehicle. 